Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 11Phase 1/2 7Phase NA 2Phase 3 2Phase 4 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Follicular 15Lymphoma 15Multiple Myeloma 14Lymphoma, Mantle-Cell 14Leukemia, Myeloid, Acute 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Non-Hodgkin 13Leukemia 13Hodgkin Disease 13Congenital Abnormalities 13Burkitt Lymphoma 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Chronic-Phase 12Lymphoma, Large-Cell, Immunoblastic 11Leukemia, Myeloid, Accelerated Phase 11Myeloproliferative Disorders 10Myelodysplastic Syndromes 10Recurrence 9Primary Myelofibrosis 9Lymphoma, T-Cell, Cutaneous 9Dendritic Cell Sarcoma, Interdigitating 9Blast Crisis 8Sezary Syndrome 7Mycosis Fungoides 7Leukemia, Myelomonocytic, Chronic 7Anemia, Refractory, with Excess of Blasts 7Waldenstrom Macroglobulinemia 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6

Interventions

Standard of Care 9Exercise 9Educational Status 8Practice Guidelines as Topic 7Methods 7Blood Specimen Collection 7Early Intervention, Educational 6Palliative Care 5Interviews as Topic 5Behavior Therapy 5fludarabine 4Surveys and Questionnaires 4Physical Therapy Modalities 4Cyclophosphamide 4Magnetic Resonance Spectroscopy 3Health Promotion 3Granulocyte Colony-Stimulating Factor 3pegylated granulocyte colony-stimulating factor 2fludarabine phosphate 2Whole-Body Irradiation 2Therapeutic Touch 2Stem Cell Transplantation 2Restraint, Physical 2Radiosurgery 2Patient Navigation 2Parenteral Nutrition 2Low-Level Light Therapy 2Etoposide 2Cytarabine 2Control Groups 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Hematologic Neoplasms × fludarabine phosphate × Clear all
NCT02880293 2024-12-06

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Memorial Sloan Kettering Cancer Center

Phase NA Completed
44 enrolled 8 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT01247688 2013-12-12

UCALL

Baylor College of Medicine

Phase NA Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡